HRP20120490T1 - Spojevi za inhibiciju napredovanja mitoze - Google Patents

Spojevi za inhibiciju napredovanja mitoze Download PDF

Info

Publication number
HRP20120490T1
HRP20120490T1 HRP20120490TT HRP20120490T HRP20120490T1 HR P20120490 T1 HRP20120490 T1 HR P20120490T1 HR P20120490T T HRP20120490T T HR P20120490TT HR P20120490 T HRP20120490 T HR P20120490T HR P20120490 T1 HRP20120490 T1 HR P20120490T1
Authority
HR
Croatia
Prior art keywords
aliphatic
group
fluoroaliphatic
compound according
fluoro
Prior art date
Application number
HRP20120490TT
Other languages
English (en)
Croatian (hr)
Inventor
Christopher@F@@Claiborne
Todd@B@@Sells
Stephen@G@@Stroud
Original Assignee
Millennium@Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120490(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium@Pharmaceuticals filed Critical Millennium@Pharmaceuticals
Publication of HRP20120490T1 publication Critical patent/HRP20120490T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20120490TT 2006-11-16 2007-11-14 Spojevi za inhibiciju napredovanja mitoze HRP20120490T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
HRP20120490T1 true HRP20120490T1 (hr) 2012-07-31

Family

ID=39315133

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120490TT HRP20120490T1 (hr) 2006-11-16 2007-11-14 Spojevi za inhibiciju napredovanja mitoze
HRP20150047TT HRP20150047T1 (en) 2006-11-16 2015-01-13 Compound for inhibiting mitotic progression

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20150047TT HRP20150047T1 (en) 2006-11-16 2015-01-13 Compound for inhibiting mitotic progression

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2086981B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101342014B1 (enExample)
CN (2) CN103483343B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2086981T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2528793T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX2009004670A (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ597252A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2497772T3 (enExample)
PT (2) PT2086981E (enExample)
RS (2) RS53788B1 (enExample)
SG (2) SG10201503350TA (enExample)
SI (2) SI2497772T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1771450T3 (pl) 2004-05-14 2008-05-30 Millennium Pharm Inc Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
TW201026703A (en) * 2008-12-05 2010-07-16 Millennium Pharm Inc Thiolactams and uses thereof
AU2009330727B2 (en) 2008-12-22 2016-07-28 Millennium Pharmaceuticals, Inc. Combination of Aurora kinase inhibitors and anti-CD20 antibodies
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2585465B1 (en) * 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105209042B (zh) * 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. オーロラキナーゼ阻害剤と抗cd30抗体の併用
US20180263979A1 (en) * 2014-12-23 2018-09-20 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
JP6966425B2 (ja) 2015-09-09 2021-11-17 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Hp1の機能に着目した抗癌剤のスクリーニング方法及び評価系
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN119343334A (zh) 2022-04-07 2025-01-21 伊莱利利公司 制造kras g12c抑制剂的方法
EP4504209A1 (en) 2022-04-08 2025-02-12 Eli Lilly and Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
AU2023297941A1 (en) 2022-06-30 2025-01-16 Eli Lilly And Company Kras g12c inhibitor for treating cancer
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
CA1138863A (en) 1979-02-07 1983-01-04 Norman W. Gilman Benzazepine-derivatives
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ330973A (en) 1996-03-08 2000-03-27 Zeneca Ltd Azolobenzazepine derivatives as neurologically active agents
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
AU744636B2 (en) * 1997-09-29 2002-02-28 Meiji Seika Pharma Co., Ltd. Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ATE403644T1 (de) 1999-12-06 2008-08-15 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
KR100947185B1 (ko) 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
PL1771450T3 (pl) 2004-05-14 2008-05-30 Millennium Pharm Inc Związki i sposoby do inhibicji postępu mitozy przez hamowanie kinazy Aurora
EP1812424A4 (en) 2004-11-17 2009-07-08 Miikana Therapeutics Inc Kinase Inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
JP2010500352A (ja) 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
MX343391B (es) 2016-11-04
US20190031662A1 (en) 2019-01-31
JP5452811B2 (ja) 2014-03-26
BRPI0718803B1 (pt) 2020-11-17
NO343338B1 (no) 2019-02-04
ES2537451T3 (es) 2015-06-08
BRPI0718803B8 (pt) 2021-05-25
NZ597252A (en) 2013-06-28
SG176443A1 (en) 2011-12-29
TW200829589A (en) 2008-07-16
PL2086981T3 (pl) 2012-09-28
HK1175777A1 (en) 2013-07-12
US20150166545A1 (en) 2015-06-18
ES2384123T3 (es) 2012-06-29
EP2497772A1 (en) 2012-09-12
US10836766B2 (en) 2020-11-17
NZ611898A (en) 2015-01-30
HK1175778A1 (en) 2013-07-12
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
CA2669680A1 (en) 2008-05-29
DK2497772T3 (en) 2015-01-19
JP2012006965A (ja) 2012-01-12
US9765076B2 (en) 2017-09-19
PH12012502057A1 (en) 2015-09-14
CL2007003244A1 (es) 2008-04-04
US20240400567A1 (en) 2024-12-05
ZA200903279B (en) 2010-07-28
HRP20150047T1 (en) 2015-03-13
MX348568B (es) 2017-06-20
PT2497772E (pt) 2015-02-05
MY153243A (en) 2015-01-29
TWI401255B (zh) 2013-07-11
CR20140544A (es) 2015-01-12
CA2669680C (en) 2012-04-10
CN101547924A (zh) 2009-09-30
EP2086981B1 (en) 2012-05-02
IL198690A0 (en) 2010-02-17
MA30988B1 (fr) 2009-12-01
US20080167292A1 (en) 2008-07-10
SI2086981T1 (sl) 2012-12-31
EA015779B1 (ru) 2011-12-30
SI2497772T1 (sl) 2015-03-31
CN103483343B (zh) 2016-06-01
SG10201503350TA (en) 2015-06-29
AR064246A1 (es) 2009-03-25
KR101110458B1 (ko) 2012-03-13
WO2008063525A1 (en) 2008-05-29
DK2086981T3 (da) 2012-08-06
CR10782A (es) 2009-06-24
ES2528793T3 (es) 2015-02-12
EP2944639B1 (en) 2017-01-04
US20110312942A1 (en) 2011-12-22
UA94129C2 (ru) 2011-04-11
EP2497773B1 (en) 2015-02-25
PH12012502057B1 (en) 2018-10-24
KR20090091173A (ko) 2009-08-26
JP2010510215A (ja) 2010-04-02
RS52313B (sr) 2012-12-31
EA200970486A1 (ru) 2009-10-30
EP2497773A1 (en) 2012-09-12
BRPI0718803A2 (pt) 2013-12-03
CY1112828T1 (el) 2016-02-10
CR20140154A (es) 2014-07-23
KR20110113210A (ko) 2011-10-14
ATE556076T1 (de) 2012-05-15
AU2007322046A1 (en) 2008-05-29
US20110312943A1 (en) 2011-12-22
JP5102839B2 (ja) 2012-12-19
HK1217699A1 (en) 2017-01-20
NO20091864L (no) 2009-06-15
KR101342014B1 (ko) 2013-12-19
NZ577042A (en) 2012-03-30
PL2497772T3 (pl) 2015-05-29
CN103483343A (zh) 2014-01-01
US8026246B2 (en) 2011-09-27
EP2086981A1 (en) 2009-08-12
US20210214361A1 (en) 2021-07-15
EP2497772B1 (en) 2014-10-29
GEP20125459B (en) 2012-03-26
JP2014055166A (ja) 2014-03-27
AU2007322046B2 (en) 2012-04-05
US9988384B2 (en) 2018-06-05
US11958855B2 (en) 2024-04-16
EP2944639A1 (en) 2015-11-18
HK1134672A1 (en) 2010-05-07
RS53788B1 (sr) 2015-06-30
CN101547924B (zh) 2013-09-25

Similar Documents

Publication Publication Date Title
HRP20120490T1 (hr) Spojevi za inhibiciju napredovanja mitoze
ES2970074T3 (es) Inhibidor de ATR y su aplicación
CN101675053B (zh) 磷酸肌醇3-激酶抑制剂化合物及使用方法
RU2345996C1 (ru) Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
JP2010510215A5 (enExample)
HRP20131051T1 (hr) Inhibitori proteinskih kinaza
HRP20120785T1 (hr) Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze
ATE361916T1 (de) Pyrimidine verbindungen
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
HRP20160967T1 (hr) Heterociklički spojevi korisni kao pdk1 inhibitori
HRP20140437T1 (hr) Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora
JO3108B1 (ar) بيرروليدينونات أروماتية مخلطة مندمجة كمثبطات syk
ME00972B (me) NOVI DERIVATI 6-TRIAZOLOPIRIDAZINSULFANIL BENZOTIAZOLA I BENZIMIDAZOLA, POSTUPAK ZA NJIHOVO DOBIJANJE l UPOTREBA KAO LJEKOVA l FARMACEUTSKIH KOMPOZICIJA l NOVA UPOTREBA KAO INHIBITORA MET-a
RU2341527C1 (ru) Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
RU2005135338A (ru) Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
EA201991025A1 (ru) Липосомальный препарат для применения для лечения злокачественного новообразования
WO2010002779A2 (en) Naphthyridininones as aurora kinase inhibitors
JP2015502371A5 (enExample)
SE0300091D0 (sv) Novel compounds
JP2014524449A5 (enExample)
AR054863A1 (es) DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA
RU2007125661A (ru) Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина
RU2011153613A (ru) Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет